Clin Mol Hepatol.
2021 Apr;27(2):221-235. 10.3350/cmh.2020.0239.
Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
- Affiliations
-
- 1Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Jacksonville, FL, USA
- 2Division of Gastroenterology and Hepatology, Department of Medicine, University of Minnesota, Minneapolis, MN, USA
- 3Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA, USA
- KMID: 2514762
- DOI: http://doi.org/10.3350/cmh.2020.0239
Abstract
- Nonalcoholic fatty liver disease (NAFLD) is a multisystemic disease and a rapidly growing cause of chronic liver disease in children and adults worldwide. Diagnosis and management of extrahepatic manifestations of NAFLD, including cardiovascular disease (CVD), type 2 diabetes mellitus, metabolic syndrome, chronic kidney disease, obstructive sleep apnea, polycystic ovarian syndrome, hypothyroidism, psoriasis, and extrahepatic malignancy are crucial for the treatment of patients with NAFLD. The leading cause of death in NAFLD is primarily from CVD, followed by liver-related mortality, extrahepatic cancer, liver cancer, and diabetes-related mortality. Therefore, clinicians need to identify high-risk patients earlier in the disease course and be aware of the extrahepatic manifestations of NAFLD to improve liver disease outcomes. In this review, we focus on the monitoring and management of the extrahepatic manifestations of NAFLD.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease
- Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
- Nonalcoholic fatty liver disease: pathogenesis and treatment
- Elevated serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease
- The Diagnosis of Nonalcoholic Fatty Liver Disease
